Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$207.1M
59M shares
52-week range
$2.77 – $15.55
4% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.34%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.09B | $1.17B | $1.13B | $1.12B | $1.12B | $1.08B |
| Cost of revenue | $323.0M | $323.0M | $365.0M | $354.6M | $370.9M | $394.2M | $400.9M |
| Gross profit | $786.0M | $763.0M | $800.0M | $774.9M | $749.9M | $728.9M | $679.5M |
| Gross margin | 70.9% | 70.3% | 68.7% | 68.6% | 66.9% | 64.9% | 62.9% |
| R&D | $62.0M | $61.0M | $63.0M | $65.0M | $85.2M | $78.8M | $21.5M |
| Operating income | $502.0M | $487.0M | $492.0M | $378.1M | $229.6M | $174.2M | $329.3M |
| EBITDA | $536.0M | $524.0M | $533.0M | $334.5M | $245.4M | $199.0M | $294.7M |
| Net income | $432.0M | $427.6M | $414.8M | $223.6M | $70.4M | $78.3M | $95.4M |
| Net margin | 39.0% | 39.4% | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| EPS (diluted) | 7.58 | 7.50 | 7.31 | 3.89 | 1.22 | 1.34 | 1.62 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $1.59 | $1.55–$1.62 | 3 |
| 2027 | $1.1B | $1.74 | $1.73–$1.74 | 3 |
| 2028 | $1.1B | $1.93 | $1.42–$2.39 | 3 |
| 2029 | $1.1B | $2.96 | $2.95–$2.97 | 1 |
Forward consensus · source: Financial Modeling Prep
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
www.embecta.comNo one on the platform currently holds EMBC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 144,287 | $1.3M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-28 | $0.0100 | 2026-06-15 |
| 2026-02-27 | $0.1500 | 2026-03-17 |
| 2025-12-05 | $0.1500 | 2025-12-18 |
| 2025-08-29 | $0.1500 | 2025-09-15 |
| 2025-05-28 | $0.1500 | 2025-06-13 |
| 2025-02-28 | $0.1500 | 2025-03-14 |
| 2024-12-06 | $0.1500 | 2024-12-18 |
| 2024-08-27 | $0.1500 | 2024-09-13 |
| 2024-05-24 | $0.1500 | 2024-06-14 |
| 2024-02-27 | $0.1500 | 2024-03-15 |
No one on the platform has traded EMBC yet.
| $620M |
| — |
| MRVIMaravai LifeSciences Holdings, Inc. | $6.22 | +1.63% | $1.7B | — |
| MYGNMyriad Genetics, Inc. | $5.88 | +8.29% | $555M | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-01 |
| $0.1500 |
| 2023-12-15 |
| 2023-08-24 | $0.1500 | 2023-09-13 |
Trading at 3.7× earnings vs its 9.6× historical median P/E.
Fair value ≈ $8.48 · price $3.31 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$EMBC near term should absolutely be between 6-7$🤯
View on StockTwits ↗$EMBC this has “underestimated” written all over it.
View on StockTwits ↗$EMBC ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - VOLUME >>> GREAT SETUP <<< >>>>> #LISTEN! <<<<< 🎯 XXX% ON TAP >> GREAT SETUP! << >>>>>>> LISTEN! <<<<<<<
View on StockTwits ↗$EMBC Expansion, increase, modernization of capacities!!! 💪✅ https://www.linkedin.com/posts/were-excited-to-be-entering-the-next-ugcPost-7475461475772428289-Ap7g/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAF8uyZsBJ4KgRdzHO0a-goDvvWzFA3Mt4oA&utm_campaign=share_via
View on StockTwits ↗$EMBC ⚡️WHAT DID I SAY?!⚡️ >>> STOCK OF INTEREST 🎯 XX% +++++ >>>>>>> LISTEN! <<<<<<<
View on StockTwits ↗$EMBC ✅ https://www.linkedin.com/posts/today-we-welcome-sai-yedavelli-to-embecta-share-7475176693859655681-TfgN/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAF8uyZsBJ4KgRdzHO0a-goDvvWzFA3Mt4oA&utm_campaign=copy_link
View on StockTwits ↗$EMBC Check out the profiles of people congratulating Nimish on his appointment! https://www.linkedin.com/posts/embecta_were-pleased-to-welcome-nimish-muzumdar-activity-7472685548176838656-cngj?utm_source=share&utm_medium=member_ios&rcm=ACoAAF8uyZsBJ4KgRdzHO0a-goDvvWzFA3Mt4oA
View on StockTwits ↗$EMBC https://www.linkedin.com/posts/rmhayes1_glp1-drugdelivery-combinationproducts-share-7474805979520323584-tjoK/?utm_source=share&utm_medium=member_ios&rcm=ACoAAF8uyZsBJ4KgRdzHO0a-goDvvWzFA3Mt4oA
View on StockTwits ↗$EMBC Some fund absorbed the entire volume!!! 🚀🚀🚀✅
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.